虽然在过去的10余年里,恶性肿瘤生存率呈现逐渐上升趋势,但我国预后较好的肿瘤,如乳腺癌 (82.0%)、甲状腺癌 (84.3%) 和前列腺癌 (66.4%) 的5年生存率仍与美国等发达国家存在差距 (90.9%、98%和99.5%)。原因主要为目前我国的临床早诊率低、以及晚期病例临床诊治不规范等。因此,我国应扩大相关肿瘤的筛查及早诊早治覆盖面、肿瘤临床诊治规范化和同质化,降低我国恶性肿瘤死亡率。
肿瘤相关标志物抗体、抗原推荐
标志物 |
货号 |
产品描述 |
临床应用意义 |
CEA |
Anti-h CEA 5905 SP-5 |
最广谱指标,升高可见于结直肠癌、胃癌、肺癌、胰腺癌等
|
|
CEA |
Anti-h CEA 5909 SP-5 |
||
CEA |
Anti-h CEA 5910 SPTN-5 |
||
CEA |
Anti-h CEA 5911 SP-1 |
||
CEA |
Anti-h CEA 5912 SP-1 |
标志物 |
货号 |
产品描述 |
临床应用意义 |
hCG |
Anti-hCG beta 5004 SP-1 |
滋养层肿瘤、生殖细胞肿瘤、睾丸肿瘤等 |
|
hCG |
Anti-hCG beta 5006 SP-5 |
||
hCG |
Anti-hCG beta 5008 SP-5 |
||
hCG |
Anti-hCG beta 5011 SPRN-1 |
||
hCG |
Anti-hCG beta 5012 SPRN-5 |
||
hCG |
Anti-hCG 5014 SPTN-5 |
||
hCG |
Anti-hCG 5016 SPRN-5 |
||
CA15-3 |
Anti-h CA15-3 4404 SPTN-5 |
乳腺癌 |
|
CA15-3 |
Anti-h CA15-3 R4406 SPTN-5 |
||
PSA |
Anti-h PSA 8301 SPRN-5 |
前列腺癌 |
|
PSA |
Anti-h PSA 8311 SPRN-1 |
||
PSA |
Anti-h PSA 8312 SPRN-5 |
||
PSA |
Anti-h PSA 8313 SPTN-5 |
||
CA125 |
Anti-h CA125 4601 SPTN-5 |
卵巢癌 |
|
CA125 |
Anti-h CA125 4602 SPTN-5 |
||
HE4 |
Anti-h HE4 4501 SPTN-5 |
||
HE4 |
Anti-h HE4 4502 SPTN-5 |
||
HE4 |
Anti-h HE4 4503 SPTN-5 |
||
HE4 |
Anti-h HE4 4505 SPTN-5 |
||
HE4 |
Human Epididymis Protein 4 (HE4) Antigen, Recombinant >95% |
标志物 |
货号 |
产品描述 |
临床应用意义 |
AFP |
Anti-h AFP 5107 SP-1 |
原发性肝癌 |
|
AFP |
Anti-h AFP 5108 SP-5 |
||
PIVKA-II |
Anti-h PIVKA-II 12102 SPTN-5 |
||
PIVKA-II |
Anti-h PIVKA-II 12103 SPTN-5 |
||
PIVKA-II |
Anti-h PIVKA-II 12106 SPTN-5 |
标志物 |
货号 |
产品描述 |
临床应用意义 |
NSE |
Anti-h NSE 9601 SPTN-5 |
小细胞肺癌 |
|
NSE |
Anti-h NSE 9602 SPTN-5 |
||
NSE |
Recombinant NSE antigen, 100 µg |
||
ProGRP |
Anti-h ProGRP 13001 SPTN-5 |
非小细胞肺癌 |
|
ProGRP |
Anti-h ProGRP 13002 SPTN-5 |
||
CYFRA21-1 |
Anti-h CYFRA21-1 1602 SPTNZ-5 |
||
CYFRA21-1 |
Anti-h CYFRA21-1 1603 SPTNZ-5 |
||
CYFRA21-1 |
Anti-h CYFRA21-1 1604 SPTN-5 |
||
CYFRA21-1 |
Anti-h CYFRA21-1 1605 SPTN-5 |
||
CYFRA21-1 |
CYFRA21-1 (Cytokeratin Fragment) Antibody |
标志物 |
货号 |
产品描述 |
临床应用意义 |
CA19-9 |
Anti-h CA19-9 4701 SPTN-5 |
消化系统癌症,如胰腺癌、胆囊癌等 |
|
Gastrin-17 |
Anti-h Gastrin-17 11701 SPTN-5 |
胃癌筛查 |
|
Gastrin-17 |
Anti-h Gastrin-17 11702 SPTN-5 |
||
Gastrin-17 |
Anti-h Gastrin-17 11705 SPTN-5 |
||
Gastrin-17 |
Anti-h Gastrin-17 11707 SPTN-5 | ||
PG I |
Anti-h PG I 8003 SPRN-5 |
||
PG I |
Anti-h PG I 8009 SPTN-1 |
||
PG I |
Anti-h PG I 8015 SPRN-5 |
||
PG I |
Anti-h PG I 8016 SPRN-5 |
||
PG I |
Recombinant Pepsinogen I, 100 μg |
||
PG II |
Anti-h PG II 8101 SPTN-5 |
||
PG II |
Anti-h PG II 8102 SPRN-1 |
||
PG II |
Anti-h PG II 8103 SPTN-5 |
||
PG II |
Recombinant Pepsinogen II, 100 μg |
标志物 |
货号 |
产品描述 |
临床应用意义
|
CA72-4 |
Cancer Antigen 72-4 (CA72-4) Antibody |
胃癌 |
|
CA72-4 |
Cancer Antigen 72-4 (CA72-4) Antibody |
||
SCC |
Anti-h SCC 11801 SPTN-5 |
鳞癌,如食管癌、宫颈癌、肺鳞癌、膀胱癌等 |
|
SCC |
Anti-h SCC 11802 SPTN-5 |
||
SCC |
Anti-h SCC 11803 SPTN-5 |
||
SCC |
Anti-h SCC 11804 SPTN-5 |
||
Hemoglobin |
Anti-h Hemoglobin 7202 SPR-5 |
结直肠癌 |
|
Hemoglobin |
Anti-h Hemoglobin 7204 SP-5 |
||
Hemoglobin |
Hemoglobin (Hb) Antibody |
||
Hemoglobin |
Hemoglobin (Hb) Antibody |
||
CA242 |
Cancer Antigen 242 (CA242) Antibody |
胰腺癌、胃癌、大肠癌等 |
标志物 |
货号 |
产品描述 |
临床应用意义 |
B2M |
Beta-2 Microgloblulin (B2M) Antibody |
淋巴增殖性癌症 |
|
B2M |
Beta-2 Microgloblulin (B2M) Antibody |
||
Ferritin |
Anti-h Ferritin 8803 SPRN-5 |
霍奇金淋巴瘤、急性白血病、肺癌、结肠癌、肝癌、前列腺癌等 |
|
Ferritin |
Anti-h Ferritin 8806 SPTN-5 |
标志物 |
货号 |
产品描述 |
临床应用意义 |
Calcitonin |
Anti-h Calcitonin 4050 |
甲状腺癌 |
|
Calcitonin |
Anti-h Calcitonin 4051 |
||
Thyroglobulin |
Anti-h Thyroglobulin 2802 SPTN-5 |
||
Thyroglobulin |
Anti-h Thyroglobulin 2803 SPTN-5 |
||
Thyroglobulin |
Anti-h Thyroglobulin 2804 SPTN-5 |
||
Thyroglobulin |
Anti-h Thyroglobulin 2805 SPTN-5 |
标志物 |
货号 |
产品描述 |
临床应用意义 |
S100B |
Anti-h S100B 11401 SPTN-5 |
黑色素瘤和神经源性肿瘤,如神经鞘瘤和神经纤维瘤 |
|
S100B |
Anti-h S100B 11402 SPTN-5 |
||
S100B |
Anti-h S100B 11404 SPTN-5 |
||
S100B |
S100B Antigen, Recombinant >95% |
||
S100B |
Recombinant S100B, 50 μg |
联系我们
Medix Biochemica China
上海墨迪斯医疗技术有限公司
上海市闵行区浦江镇绿洲环路10号6幢11层
电话:021-68119180,68119105,68119181
邮箱:medixchina@medixbiochemica.com